BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 29633255)

  • 21. JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity.
    Xun J; Wang D; Shen L; Gong J; Gao R; Du L; Chang A; Song X; Xiang R; Tan X
    Oncotarget; 2017 Mar; 8(13):21918-21929. PubMed ID: 28423536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.
    Zhang M; Pan Y; Dorfman RG; Chen Z; Liu F; Zhou Q; Huang S; Zhang J; Yang D; Liu J
    Oncotarget; 2016 Apr; 7(16):22285-94. PubMed ID: 26993777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
    Liu C; Lv D; Li M; Zhang X; Sun G; Bai Y; Chang D
    Int J Oncol; 2017 Jun; 50(6):2079-2090. PubMed ID: 28440397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
    Zhao J; Jin W; Yi K; Wang Q; Zhou J; Tan Y; Xu C; Xiao M; Hong B; Xu F; Zhang K; Kang C
    Pharmacol Res; 2021 Sep; 171():105764. PubMed ID: 34246782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.
    Boulding T; McCuaig RD; Tan A; Hardy K; Wu F; Dunn J; Kalimutho M; Sutton CR; Forwood JK; Bert AG; Goodall GJ; Malik L; Yip D; Dahlstrom JE; Zafar A; Khanna KK; Rao S
    Sci Rep; 2018 Jan; 8(1):73. PubMed ID: 29311580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Zhou Y; Jin X; Ma J; Ding D; Huang Z; Sheng H; Yan Y; Pan Y; Wei T; Wang L; Wu H; Huang H
    Cancer Res; 2021 Mar; 81(6):1486-1499. PubMed ID: 33419772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.
    Hsu HC; Liu YS; Tseng KC; Yang TS; Yeh CY; You JF; Hung HY; Chen SJ; Chen HC
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):11-21. PubMed ID: 25060070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway.
    Li Y; Tao L; Zuo Z; Zhou Y; Qian X; Lin Y; Jie H; Liu C; Li Z; Zhang H; Zhang H; Cen X; Yang S; Zhao Y
    Cancer Lett; 2019 Jul; 454():179-190. PubMed ID: 30978443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and -independent manners.
    Pollock JA; Larrea MD; Jasper JS; McDonnell DP; McCafferty DG
    ACS Chem Biol; 2012 Jul; 7(7):1221-31. PubMed ID: 22533360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human epidermal growth factor receptor 2 inhibits activating transcription factor 7 to promote breast cancer cell migration by activating histone lysine demethylase 1.
    Lin J; Mao H; Ji Z; Lin W; Wang T
    J Cancer Res Ther; 2021 Nov; 17(5):1192-1201. PubMed ID: 34850767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.
    Pledgie-Tracy A; Sobolewski MD; Davidson NE
    Mol Cancer Ther; 2007 Mar; 6(3):1013-21. PubMed ID: 17339367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells.
    Royston KJ; Udayakumar N; Lewis K; Tollefsbol TO
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28534825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms.
    Royston KJ; Paul B; Nozell S; Rajbhandari R; Tollefsbol TO
    Exp Cell Res; 2018 Jul; 368(1):67-74. PubMed ID: 29689276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor Effect of Demethylzeylasteral (T-96) on Triple-Negative Breast Cancer via LSD1-Mediate Epigenetic Mechanisms.
    Shen Z; Gu Y; Jiang R; Qian H; Li S; Xu L; Gu W; Zuo Y
    Anal Cell Pathol (Amst); 2022; 2022():2522597. PubMed ID: 36276611
    [No Abstract]   [Full Text] [Related]  

  • 35. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
    Lim S; Janzer A; Becker A; Zimmer A; Schüle R; Buettner R; Kirfel J
    Carcinogenesis; 2010 Mar; 31(3):512-20. PubMed ID: 20042638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition.
    Sharma M; Tollefsbol TO
    Exp Cell Res; 2022 Jul; 416(1):113160. PubMed ID: 35447103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 39. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
    Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
    Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.